Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 7, 2016, Pages 728-737

  Butt, A A ^a,b,c   Yan, P ^a   Marks, K ^c   Shaikh, O S ^a,d   Sherman, K E ^e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b HAMAD MEDICAL CORPORATION   (Qatar)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT;

ADD ON THERAPY; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PRESCRIPTION; PRIORITY JOURNAL; AGED; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; GENETICS; GENOTYPE; HEPACIVIRUS; ISOLATION AND PURIFICATION; MIDDLE AGED; VETERAN;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; VETERANS;

EID: 84989214572     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13748     Document Type: Article

References (27)

1. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604–14.
2. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211–21.
3. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879–88.
4. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483–93.
5. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878–87.
6. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015; 386: 1537–45.
7. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015; 163: 1–13.
8. Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES. Liver Int 2016; 36: 651–8.
9. Butt AA, Yan P, Shaikh OS, et al. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings. J Viral Hepat 2015; 22: 691–700.
10. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983–92.
11. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973–82.
12. Butt AA, Wang X, Budoff M, Leaf DA, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009; 49: 225–32.
13. Butt AA, Wang X, Moore CM. Effect of HCV and its treatment upon survival. Hepatology 2009; 50: 387–92.
14. Butt AA, Wang X, Fried LF. HCV infection and the incidence of chronic kidney disease. Am J Kid Dis 2011; 57: 396–402.
15. Mohanty A, Erqou S, McGinnis KA, et al. Therapy for hepatitis C virus infection increases survival of patients with pretreatment anemia. Clin Gastroenterol Hepatol 2013; 11: 741–7.
16. FDA. Viekira Pak product label. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf (accessed 10 July 2016).
17. Harvoni product label approved by FDA. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205834s000lbl.pdf (accessed 7 March, 2016)
18. FDA. Simeprevir product label. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdf (accessed 7 March 2016).
19. Butt AA, Yan P, Bonilla H, et al. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: results from ERCHIVES. Hepatology 2015; 62: 365–74.
20. Butt AA, Yan P, Lo Re V 3rd, et al. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Int Med 2015; 175: 178–85.
21. Butt AA, McGinnis KA, Rodriguez-Barradas MC, et al. HIV infection and the risk of diabetes mellitus. AIDS 2009; 23: 1227–34.
22. WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, WHO/NMH/NHD/MNM/11 12011.
23. Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther 2016; 43: 1276–92.
24. Bourliere M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015; 15: 397–404.
25. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015; 15: 645–53.
26. Alqahtani SA, Afdhal N, Zeuzem S, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials. Hepatology 2015; 62: 25–30.
27. Banerjee D, Reddy KR. Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther 2016; 43: 674–96.